Terns Pharmaceuticals’ experimental GLP-1 obesity drug TERN-601 showed a 5.5% reduction in body weight in a small study. The drug aims to be an oral alternative to injectable obesity medicines, with plans for a larger mid-stage clinical trial next year. The Phase 1 trial enrolled 37 obese or overweight participants who received TERN-601 or a placebo. The drug showed dose-dependent weight loss, with 67% of high-dose participants achieving a 5.5% weight reduction. Terns hopes to advance TERN-601 into Phase 2 development in 2025. Other companies are also developing oral obesity medications with promising weight-loss results.
Source link
Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study
